Advertisement

Molecular Cancer

, 17:77 | Cite as

LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis

  • Yanyan Tang
  • Yi He
  • Ping Zhang
  • Jinpeng Wang
  • Chunmei Fan
  • Liting Yang
  • Fang Xiong
  • Shanshan Zhang
  • Zhaojian Gong
  • Shaolin Nie
  • Qianjin Liao
  • Xiayu Li
  • Xiaoling Li
  • Yong Li
  • Guiyuan Li
  • Zhaoyang Zeng
  • Wei Xiong
  • Can Guo
Open Access
Review

Abstract

Some of the key steps in cancer metastasis are the migration and invasion of tumor cells; these processes require rearrangement of the cytoskeleton. Actin filaments, microtubules, and intermediate filaments involved in the formation of cytoskeletal structures, such as stress fibers and pseudopodia, promote the invasion and metastasis of tumor cells. Therefore, it is important to explore the mechanisms underlying cytoskeletal regulation. The ras homolog family (Rho) and Rho-associated coiled-coil containing protein serine/threonine kinase (ROCK) signaling pathway is involved in the regulation of the cytoskeleton. Moreover, long noncoding RNAs (lncRNAs) have essential roles in tumor migration and guide gene regulation during cancer progression. LncRNAs can regulate the cytoskeleton directly or may influence the cytoskeleton via Rho/ROCK signaling during tumor migration. In this review, we focus on the regulatory association between lncRNAs and the cytoskeleton and discuss the pathways and mechanisms involved in the regulation of cancer metastasis.

Keywords

Long noncoding RNA Cytoskeleton Rho/ROCK signaling Cancer metastasis 

Abbreviations

AFAP1-AS1

actin lament associated protein 1 antisense RNA1

ASTN1

astrotactin 1

CCAT2

colon cancer associated transcript 2

CDC42

cell division cycle 42

ceRNA

competitive endogenous messenger RNA

Dreh

downregulated in hepatocellular carcinoma

EMT

epithelial mesenchymal transition

F-actin

filamentous actin

FSCN1

fascin actin-bundling protein 1

GAS5

Growth Arrest­Specific 5

GTPase

Rho guanosine triphosphatase

HOTAIR

Hox transcript antisense intergenic RNA

LIMK

LIM kinase

LncRNAs

long noncoding RNAs

MALAT1

metastasis-associated lung adenocarcinoma transcript 1

MEG3

maternally expressed 3

MLC

myosin light chain

MYH9

Myosin-9

MYPT1

myosin phosphatase 1

NPC

nasopharyngeal carcinoma

PAK

p21 activated kinase

PCDHA1

protocadherin alpha 1

PTCSC2

papillary thyroid cancer susceptibility candidate 2

PVT1

Pvt1 oncogene

RhoA

Ras homolog family member A

ROCK

Rho-associated coiled-coil containing protein serine/threonine kinases

TDRG1

testis development–related gene 1

UCA1

urothelial cancer- associated 1

Background

Cell migration requires cytoskeletal reorganization, which plays a critical role in cancer metastasis [1, 2]. In particular, some classical signaling pathways are involved during cytoskeletal reorganization, such as the ras homolog family (Rho) and Rho-associated coiled-coil protein kinase (ROCK) signaling pathway [3, 4].

Approximately 75% of human genomic DNA can be transcribed into RNA, but only 2–3% of the genes encode a protein; therefore, in the entire transcriptome, the proportion of noncoding RNAs is far higher than the proportion of protein-coding mRNAs [5]. Among the former, lncRNA is a transcript longer than 200 nucleotides and cannot code for a protein; it can play an important role in the process of tumor metastasis through multiple mechanisms [6]. The abnormal expression of lncRNAs is related to the poor prognosis of patients with cancer. Studies have revealed that the lncRNA AFAP1-AS1 promotes the invasion and migration of nasopharyngeal carcinoma (NPC) cells by stimulating stress fiber formation [7]. The lncRNA Pvt1 oncogene (PVT1) is related to poor prognosis by inhibiting apoptosis in colorectal cancers [8]. PVT1 is an indicator of poor prognosis for gastric cancer and promotes cell proliferation by regulating the epigenetic expression of p15 and p16 [9]. Depletion of the lncRNA urothelial cancer associated 1 (UCA1) induces radiosensitivity and decreases proliferative capacity [10]. Thus, lncRNAs can promote tumor cell invasion, migration, proliferation, and radiosensitivity and inhibit tumor cell apoptosis, thereby accelerating tumor progression, predisposing cancer patients to distant metastasis, and resulting in poor prognosis.

LncRNAs can directly interact with cytoskeletal proteins to change the three-dimensional structure of cells and can regulate the cytoskeleton through the Rho/ROCK signaling pathway. Therefore, the interactions among lncRNAs, Rho/ROCK signaling, and the cytoskeleton underlie the ability of a cell to become motile, eventually leading to tumor migration [7, 11]. This review describes the current knowledge about the mechanisms underlying cytoskeleton reprogramming, followed by discussion of the roles of lncRNAs. The interaction between lncRNAs and cell migration suggests new therapeutic targets in cancer metastasis.

Cytoskeletal reorganization and cancer cell movement

The cytoskeleton refers to the structure of the protein fiber network in eukaryotic cells. It plays an important role in the maintenance of cell shape, cell movement, transportation of substances in cells, and cytokinesis. Eukaryotic cells contain three main types of cytoskeletal filaments: microfilaments, microtubules, and intermediate filaments [12].

Microfilaments are also called actin filaments. They are approximately 7 nm in diameter and are composed of two strands of spiral fibers, which are formed by actin polymerization [13]. The basic unit of the microfilament is globular actin (also known as G-actin). Actin monomers, one after another, link to form an actin chain, and two actin chains twist around each other to form a strand of microfilament [14]. This actin polymer is filamentous actin (F-actin). The main functions of microfilaments are the formation of stress fibers, cell movement, and cytokinesis [15].

The structure and function of microfilaments is regulated by a variety of proteins. These proteins are associated with the microfilament and are known as microfilament-associated proteins; some examples include capping proteins, Arp2/3 complex, cofilin, etc. [16, 17].

The capping protein can selectively block one end of filamentous F-actin, resulting in the shortening or extension of the microfilament, which is vital for the high motility of cancer cells [18]. Research has shown that the capping protein scinderin (SCIN) regulates actin and then participates in the migration of tumor cells. In addition, the silencing of SCIN in vitro and in vivo significantly inhibits the formation of filopodia and reduces the migratory ability of gastric cancer cells [19]. The Arp2/3 complex is an actin-related protein and can nucleate the microfilament (nucleation) [20]. The entire complex can be bound to the microfilament to allow new microfilaments to be generated. In tumor cells, the function of the Arp2/3 complex is related to the movement of the lamellipodia [21]. Cofilin is a family of actin-binding proteins that disassemble microfilaments [22]. The depolymerization of cofilin can change the adhesion between cells and the extracellular matrix and ultimately promote cell migration [23, 24]. Fascin is a type of actin-bundling protein [25]. The primary functions of fascin are related to adhesion and the formation of filopodia in the movement of cancer cells [26].

Microtubules have a diameter of 25 nm [27]. They are composed of α and β tubulin subunits that form tubulin dimers [28]. Microtubules function by resisting compression and bending to maintaining cell morphology [29]. During cell migration, microtubules, together with the attached dynein, may release a signal to promote focal adhesion depolymerization [30].

The diameter of an intermediate filament is 10 nm, which is the size between microtubules and microfilaments. This structure is the most stable cytoskeletal component and plays a major role in supporting the cell [31]. Microtubules and microfilaments are assembled by spherical proteins, and intermediate fibers are assembled by long, rod-shaped proteins [32]. The intermediate filament proteins can be divided into six types based on similarities in amino acid sequence and protein structure: acidic and basic keratins, vimentin, neurofilaments, nuclear lamin, and nestin. Vimentin is the most widely distributed of all intermediate filament proteins [33, 34, 35]. Vimentin regulates cell adhesion molecules and other components and is involved in tumor cell adhesion, the epithelial–mesenchymal transition (EMT), migration, and invasion [36, 37, 38].

When invading the dense extracellular matrix, cancer cells need to have a high degree of deformability. The network structure of fibers that is composed of microfilaments and various microfilament binding proteins under the plasma membrane is called the cell cortex [39]. The cell cortex can push the cell membrane to form protrusions, including lamellipodia, filopodia, and invadopodia [40].

Lamellipodia are at the front end of a migrating cell and contain actin filament branching structures that form an actomyosin branch, which is more mature, and then extend to form lamellar protrusions. Lamellipodia usually help the cell move forward and can also drive random or continuous cell migration that is associated with the migratory phenotype of tumor cells [41]. Lamellipodia generate the driving force for cell migration [42].

Filopodia are small fingerlike cell protrusions. They contain an F-actin parallel fascicular arrangement. Filopodia are formed by actin polymerization, extending to the front end of the cell, and are especially prominent in migrating cells [43]. The contractility of filopodia is weaker than that of lamellipodia. Nonetheless, in some highly invasive tumor cells, lamellipodia are not formed, but a large number of filopodia can be observed [44, 45]. Therefore, filopodia may be associated with the invasive phenotype of tumor cells.

The invadopodia is rich in actin microfilaments and adhesion proteins, such as integrin, focal adhesion kinase (FAK), and vinculin, and forms a ring around the actin bundles [13]. The formation of invadopodia releases a variety of matrix metalloproteinases (MMPs) and degrades the extracellular matrix (ECM) to promote cell invasion [46]. ECM degradation mediated by invadopodia can also generate cell traction, which helps tumor cells to invade new sites [47].

Interestingly, fast moving cells mainly form lamellipodia, while nearly immobile cells have lamellipodia and filopodia. Lamellipodia, filopodia, and invadopodia can remodel the cytoskeleton by changing microfilaments, microtubules, and intermediate filaments. In the process of tumor cell migration, cytoskeletal reorganization is regulated by non-coding RNA and signaling pathways [48, 49] (Fig. 1).
Fig. 1

LncRNAs regulate the cytoskeleton and related proteins in cancer. LncRNAs can directly regulate the cytoskeleton and related proteins in various cancers. The lncRNA Dreh can inhibit the expression of intermediate filaments by binding to them and can prevent metastasis by changing the cytoskeletal structure and morphology of cancer cells. The lncRNA LINC00152 is involved in cytoskeletal remodeling and affects F-actin reorganization. LOC344887, CCAT2, and HOTAIR regulate vimentin. PTCSC2 regulates actin filaments via binding to MYH9

LncRNAs regulate the cytoskeleton in cancer

lncRNAs can affect the migration of tumor cells by regulating the cytoskeleton or related proteins [50, 51, 52]. The most direct evidence comes from the function of a lncRNA called “downregulated in hepatocellular carcinoma” (Dreh). The expression of Dreh is lower in cancer tissues than that in normal tissues. Patients with high expression of Dreh show a low recurrence rate and long survival time. Dreh can inhibit cell migration, and further research showed that Dreh binds to and inhibits intermediate filaments and prevents cancer cell metastasis by changing the cytoskeletal structure and cell morphology [53].

Another cytoskeleton-related lncRNA is LINC00152, which also known as cytoskeleton regulator RNA. The expression of LINC00152 is upregulated in tissue samples from various cancers. For example, Chen et al. showed that LINC00152 expression is increased in 60 human lung adenocarcinoma tissue samples relative to paired normal tissues [54]. Müller et al. reported the upregulation of LINC00152 in pancreatic cancer tissue [55]. LINC00152 is associated with a poor prognosis of tongue carcinoma with invasion and metastasis and is overexpressed in a variety of tumors, such as breast cancer, lung cancer, gastric cancer, liver cancer, gallbladder cancer, and colorectal cancer. Therefore, LINC00152 can serve as a new tumor marker [54, 56, 57, 58, 59, 60, 61]. In the breast cancer cell line MDA-MB-231, LINC00152 regulates target genes involved in cytoskeletal remodeling, including tubulin tyrosine ligase, Rho guanosine triphosphatase (GTPase) Rhobtb3, and plakophilin 4 [60]. An Ingenuity Pathway Analysis revealed that some of the target genes of LINC00152 are closely related to the cell spreading pathway, including actin polymerization–driven processes, the Rho family of GTPase promoters, and the mTORC2 complex [62, 63]. Therefore, in experiments that knocked down LINC00152 expression using a locked nucleic acid or that used fluorescently labeled F-actin, cells treated with LINC00152 are smaller, rounder, show actin reorganization, a reduction in stress fibers, and the appearance of thick actin fibers in the cortex compared with the control group [60]. In addition, according to the literature, LINC00152 may affect F-actin reorganization by regulating the expression of Golgi phosphoprotein 3 (GOLPH3) [64].

Vimentin is responsible for maintaining the integrity of the cytoskeleton and cell shape [65]. Many lncRNAs have been shown to affect vimentin, including HOX transcript antisense RNA (HOTAIR), LOC344887, and colon cancer associated transcript 2 (CCAT2). HOTAIR is relevant to small cell lung cancer invasiveness by suppressing cell adhesion–related genes such as astrotactin 1 (ASTN1) and protocadherin alpha 1 (PCDHA1) [66]. In cervical carcinoma, HOTAIR promotes the migration and invasiveness of HeLa cells by regulating the expression and organization of vimentin [51]. The inhibition of HOTAIR significantly promotes the collapse of the vimentin intermediate-filament network to lead to a decrease in cell migration and invasion [51].

Vimentin is a marker of EMT that appears during cancer metastasis. LOC344887 increases the migration and invasion of gallbladder cancer cells. In particular, LOC344887 leads to EMT by increasing the protein expression of vimentin [67]. Similarly, the lncRNA CCAT2 promotes hepatocellular cancer metastasis by positively regulating vimentin and inducing EMT [68]. Vimentin intermediate filaments are strongly involved in cell shape, focal adhesion, and motility by altering these characteristics during EMT [69].

The lncRNA papillary thyroid cancer susceptibility candidate 2 (PTCSC2) has one unspliced isoform and several spliced isoforms, all of which show thyroid-specific expression. Myosin-9 (MYH9) interacts with the lncRNA PTCSC2 [70]. Further studies have shown that MYH9 binds to the FOXE1 promoter region, PTCSC2, to regulate FOXE1 promoter activity. MYH9 participates in the generation of cell polarity, cell migration, cell–cell adhesion processes, and cytoskeleton maintenance by binding to actin filaments [71].

The expression of the lncRNA growth arrest–specific 5 (GAS5) is downregulated in glioma tissues. GAS5 inhibits the migration and invasion of U87 and U251 human glioma cell lines [72]. Mechanistically, overexpression of GAS5 increases the expression of plexin C1, which encodes a member of the plexin family. Plexins are transmembrane receptors for semaphorins, which regulate cell motility and migration by downregulating miR-222 [72]. Furthermore, plexin C1 targets cofilin by inducing cofilin inactivation rather than by decreasing the cofilin amount. Cofilin stimulates microfilament disassembly to promote cell mobility during tumor migration and invasion [72, 73]. This finding may indirectly explain why GAS5 inhibits the migration and invasion of glioma cells by reorganizing the cytoskeleton. Nevertheless, the mechanism needs further study.

The lncRNA UCA1 is upregulated in bladder cancer and induces EMT, migration, and invasion of bladder cancer cells. Mechanistically, UCA1 regulates bladder cancer cell migration and invasion by miR-145 and its target genes actin-bundling protein fascin and zinc finger E-box binding homeobox 1 and 2 (ZEB1/2) [74]. UCA1 is a direct target of hsa-miR-145 by interacting with the miR-145 binding site at exons 2 and 3 of UCA1. UCA1 mediates bladder cancer migration and invasion through the miR-145-ZEB1/2-fascin pathway [74]. Fascin localizes along the entire length of all filopodia. RNA interference of fascin reduced the number of filopodia, and the remaining filopodia had abnormal morphology and loosely bundled actin organization [75, 76].

Thus, different lncRNAs can affect the migration of tumor cells via affecting various components of the cytoskeleton and associated proteins (Fig. 1 and Table 1).
Table 1

Summary of lncRNAs regulate cytoskeletons in cancer

LncRNAs

Cytoskeletons and associated protein

Functions

Refs

Dreh

Intermediate filament

Prevent cancer cell migration through changing the cytoskeleton structure and cell morphology

[34]

LINC00152

F-actin

LINC00152 affects F-actin by regulating the expression of GOLPH3

[41, 45]

LOC344887, CCAT2, HOTAIR

Vimentin

LOC344887, CCAT2 and HOTAIR regulate the expression of vimentin

[32, 55, 57]

PTCSC2

MYH9

PTCSC2 binds MYH9 to regulate cytoskeleton

[59]

GAS5

cofilin

GAS5 suppressed glioma cell growth, migration and invasion by targeting miR-222. miR-222 induced cofilin dephosphorylation by silencing PLXNC1 gene

[61]

UCA1

FSCN1

UCA1 promotes bladder cancer cell migration and invasion by the hsa-miR-145–ZEB1/2– FSCN1 pathway

[66]

Rho/ROCK signaling in cytoskeletal reorganization

Many receptor proteins activated in the plasma membrane can initiate cytoskeletal reorganization; the signals are all mediated by the RhoGTP family and the downstream effector ROCK, which compose the Rho/ROCK signaling pathways [77, 78]. The most studied Rho GTPases can be subdivided into three classes: Rho (RhoA, RhoB, and RhoC), Rac (Rac1, Rac2, and Rac3), and cell division cycle 42 (Cdc42). Other less studied GTPases include RhoD and RhoE [79, 80, 81].

Rho aggregates actin and myosin to form stress fibers and focal adhesion complex assembly [82, 83]. RhoA is present at the cell membrane when it is active [84]. RhoA regulates the generation of actomyosin bundles, stress fibers, focal adhesions, and lamellipodia [85]. RhoB is found in endosomes and at the plasma membrane. The role of RhoB in cancer progression remains unknown, and it responds to specific signals in the tumor microenvironment [84]. RhoC modulates phagosome formation by actin cytoskeletal remodeling via mDia1 [86].

Rac primarily promotes the formation of lamellipodia and invadopodia. Rac1 localizes mainly to the plasma membrane and drives the formation of lamellipodia and invadopodia [87]. Rac2 is critical for cell adhesion to intercellular adhesion molecule-1 (ICAM-1) and for immunological synapse formation [88]. Rac3 is critical for integrating the adhesion of invadopodia to the extracellular matrix (ECM) to allow invadopodia to degrade the ECM [89].

Cdc42 promotes the formation of filopodia and induces cell migration and metastasis [90]. Other less studied GTPases, such as RhoE, can bind to ROCK1 and inhibit the activity of ROCK1 [91, 92]. Phosphoinositide dependent kinase 1 activates ROCK1 by opposing the inhibition of RhoE and then promotes cell motility [92].

The ROCK family includes two members, ROCK1 and ROCK2 [93], which are encoded by two different genes [94, 95]. ROCK1 plays a key role in the formation of stress fibers, and this isoform is mainly responsible for rigidity-dependent invadopodia activity through actomyosin contractility [96, 97]. ROCK2 is important for phagocytosis, cell contraction and stabilizing the cytoskeleton [78, 97, 98].

Rho/ROCK signals can regulate the development and balance the formation of lamellipodia, filopodia and invadopodia, and these signals promote the degradation of the extracellular matrix [99].

Rac1 promotes actin polymerization during lamellipodium formation through the WAVE complex and subsequent activation of the Arp2/3 complex [100].

Cdc42 activates the formin protein mDia2 to regulate actin nucleation and elongation of microfilaments [101, 102]. Cdc42 can also activate N-WASP to stimulate the Arp2/3 to induce actin polymerization. The straight parallel alignment of microfilaments form filopodia [99].

RhoA and RacC play important roles during the formation of invadopodia. RhoA activates mDia2 and further induces the formation of linear actin bundles to result in the elongation of invadopodia [103]. ET-1 triggers increased binding to ETAR and promotes the formation of the β-arrestin/PDZ-RhoGEF signaling complex, which activates ROCK/LIMK/cofilin through RhoC activity and generates actin remodeling and invadopodia formation [104].

In addition to regulating the formation of invadopodia, Cdc42 plays an important role in the trafficking of MMPs to the invadopodia. For example, Cdc42 induced IQGAP1 binding at invadopodia to traffic MT1-MMP and MMP14 by vesicles [105, 106]. ROCK expression increases during pancreatic cancer progression, and ROCK consequently increases the phosphorylation of MLC2. pMLC2 causes actomyosin contraction and then induces the release of the stromelysin MMP10 and the collagenase MMP13. Eventually, MMPs promote extracellular matrix remodeling to enable invasive growth [94] (Fig. 2).
Fig. 2

Rho/ROCK signaling in cytoskeleton reorganization. Rho/ROCK signaling regulates the formation of lamellipodia, filopodia and invadopodia and the release of MMPs

LncRNAs regulate Rho/ROCK signaling during tumor migration

LncRNAs can regulate cancer cell migration by targeting Rho/ROCK signaling and include metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), actin filament associated protein 1 antisense RNA1 (AFAP1-AS1), and maternally expressed 3 (MEG3) [7, 107, 108]. The lncRNA MALAT1 reduces the protein expression levels of RhoA, ROCK1, and ROCK2, indicating that MALAT1 may promote osteosarcoma cell migration by the RhoA/ROCK pathway; then, MALAT1 increases the number of actin stress fibers in osteosarcoma cells [107]. Another study suggested that MALALT1, miR-1, and cdc42 are competitive endogenous RNAs (ceRNAs) in breast cancer cells [108]. MALAT1 can bind and inhibit miR-1; miR-1 can bind to the 3’UTR of cdc42 and decrease the expression of cdc42 to induce the migration and invasion of breast cancer cells [108].

Our research group has found that the lncRNA AFAP1-AS1 leads to the loss of stress fiber formation in nasopharyngeal carcinoma by influencing the expression of RhoA/Rac2 signaling and F-actin polymerization [7]. Zhang et al. also found that increased expression of AFAP1-AS1 significantly correlates with pathological staging and lymph-vascular space invasion in patients with hepatocellular carcinoma via inhibition of RhoA/Rac2 signaling. Overall, AFAP1-AS1 may promote NPC and hepatocellular carcinoma metastases through RhoA/Rac2 signaling [109].

Wang et al. demonstrated that downregulated lncRNA MEG3 is associated with lymph node metastasis in primary thyroid cancer. Mechanistically, MEG3 suppresses the expression of Rac1 through a specific site in the 3′UTR [110]. Vinculin is another motility-associated protein that is synthesized in migrating cells, and vinculin-deficient cells extend unstable lamellipodia and filopodia. The lncRNA XLOC010623 activates the TIAM1/Rac1 and RhoA/ROCK2 signaling pathways, increases the expression of vinculin and causes the migration of adipose tissue–derived stem cells [111]. The lncRNA SchLAH physically inhibits the migration of HCC cells through RhoA and Rac1 [112]. The regulatory mechanism of the lncRNAs ABHD11-AS1 and TDRG1 are similar; they both induce the expression of RhoC and MMP during tumor progression [113, 114].

LncRNAs are involved in cancer metastasis mainly through reorganizing the cytoskeletal structure and by regulating the expression of molecules in the RhoA/ROCK pathway to result in an increased number of actin cytoskeleton fibers, stress fiber formation, formation of lamellipodia and filopodia, tumor cell adhesion, and angiogenesis. The regulatory mechanism includes ceRNA and direct binding to RAC1 and other molecules in the Rho/ROCK pathway. Understanding these relationships may provide insights into human lncRNA regulation, cytoskeletal structure, cell migration, and cancer metastasis. We present various lncRNAs in Fig. 3 and Table 2 and describe many lncRNAs that regulate tumor metastasis through cytoskeletal remodeling via the Rho/ROCK pathway. lncRNAs may be a promising target for future cancer therapy.
Fig. 3

LncRNAs regulate Rho/ROCK signaling in cancer metastasis. MALAT1 facilitates the metastasis of osteosarcoma though the RhoA/ROCK pathway and can act as ceRNA to inhibit miR-1 by targeting Cdc42, thereby inducing breast cancer cell metastasis. XLOC010623 activates the TIAM1/Rac1 and RhoA/ROCK2 signaling pathways and then increases the expression of vinculin, leading to the migration of adipose tissue–derived stem cells. SchLAH physically inhibits the migration of HCC cells through RhoA and Rac1. MEG3 downregulates Rac1 expression and is linked to primary thyroid cancer with lymph node metastasis. AFAP1-AS1 might promote NPC and HCC metastasis through RhoA/Rac2 signaling. TDRG1 induces RhoC expression and tumor progression in EOC. ABHD11-AS1 can directly bind to RhoC and upregulate the expression of its downstream molecule MMP2, thus increasing the metastatic ability of EOC

Table 2

Summary of lncRNAs regulate the Rho/ROCK signaling in cancer

LncRNAs

Rho/Rho-associated protein

Functions

Refs

MALAT1

RhoA, ROCK1 and ROCK2

MALAT1 facilitates the metastasis of osteosarcoma though RhoA/ROCK pathway

[103]

MALAT1

Cdc42

MALAT1 plays a role of Cdc42 ceRNA and induces migration by blocking miR-1 in breast cancer cells

[104]

AFAP1-AS1

RhoA/Rac2

AFAP1-AS1 might promote tumor metastasis through regulation of tumor cell adhesion and mobility via RhoA/Rac2 signaling

[7]

MEG3

Rac1

MEG3 is a novel suppressor of migration and metastasis by targeting Rac1 gene

[107]

XLOC 010623

Rac1, RhoA and ROCK2

Tetrahedral DNA nanostructures (TDNs) suppressed the transcription of XLOC010623, and activated the TIAM1/Rac1 and RhoA/ROCK2 to promote cell migration

[108]

SchLAH

RhoA and Rac1

SchLAH suppressed migration of HCC cells through downregulating RhoA and Rac1

[110]

TDRG1

RhoC

TDRG1 induced RhoC expression in epithelial ovarian carcinoma

[111]

ABHD11-AS1

RhoC

ABD11-AS1 can bind to RhoC directly in epithelial ovarian carcinoma

[112]

Conclusions

From a physics viewpoint, the development of a tumor is a biological process driven by mechanics, which is regulated by the biochemical signaling pathways of tumor cells. For example, changes in cellular mechanical properties can activate signal transduction pathways. In this review, we associate the physical movement of the cell with Rho/ROCK signaling and discuss the regulatory involvement of lncRNAs, which are significant for future research.

Many studies have shown that Rho/ROCK-mediated cytoskeletal regulation plays a key part in cancer metastasis. External factors stimulate the transition of normal cells to tumor cells. The activity of the intracellular Rho signal increases, the arrangement of cytoskeleton fibers changes, and then cell morphology is affected. In contrast, in the Rho/ROCK pathway, lncRNA-regulated specific molecules are less frequent, and we do not understand their specific mechanisms of action. Therefore, the mechanism of Rho/ROCK regulation by lncRNA and their relationship to metastasis remain to be studied.

Targeting Rho/ROCK signaling-associated lncRNAs could be useful for inhibiting the migration of cancer cells and may be a new target for the treatment of cancer metastasis. Some questions need to be addressed. For example, do lncRNAs regulate other signaling pathways that are associated with the cytoskeleton? How can the cytoskeleton be targeted via lncRNAs for clinical cancer treatment? With the development of lncRNA research and technologies for measuring cell movements, the relationship between lncRNAs and cell migration and invasion in tumor metastasis can be uncovered.

Notes

Acknowledgments

Not applicable

Funding

This work was supported by the National Natural Science Foundation of China (81472531, 81572787, 81672683, 81772928, 81702907, and 81772901), Scientific Research Projuct of the Health and Family Planning Commission of Hunan Province (B20180809) and the Natural Science Foundation of Hunan Province (2018JJ3634, 2017SK2105, 2016JC2035, and 2015JJ1022).

Availability of data and materials

Not applicable

Authors’ contributions

YT, YH and PZ wrote the manuscript and drew the figs. JW, CF and LY collected the related papers and created the Tables. FX, SZ, ZG, SN and QL helped to revise the manuscript. XL, XL, YL, GL and ZZ participated in the design of the review. WX and CG designed and revised the manuscript. All the authors read and approved the final version of the review.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Xiang T, Fan Y, Li C, Li L, Ying Y, Mu J, Peng W, Feng Y, Oberst M, Kelly K, Ren G, Tao Q. DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells. Oncotarget. 2016;7:70924–35.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Leduc C, Etienne-Manneville S. Regulation of microtubule-associated motors drives intermediate filament network polarization. J Cell Biol. 2017;216:1689–703.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Yu FX, Guan KL. The hippo pathway: regulators and regulations. Genes Dev. 2013;27:355–71.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Halon A, Donizy P, Surowiak P, Matkowski R. ERM/rho protein expression in ductal breast cancer: a 15 year follow-up. Cell Oncol (Dordr). 2013;36:181–90.CrossRefGoogle Scholar
  5. 5.
    Gong Z, Zhang S, Zeng Z, Wu H, Yang Q, Xiong F, Shi L, Yang J, Zhang W, Zhou Y, Zeng Y, Li X, Xiang B, Peng S, Zhou M, Li X, et al. LOC401317, a p53-regulated long non-coding RNA, inhibits cell proliferation and induces apoptosis in the nasopharyngeal carcinoma cell line HNE2. PLoS One. 2014;9:e110674.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Yu J, Liu Y, Gong Z, Zhang S, Guo C, Li X, Tang Y, Yang L, He Y, Wei F, Wang Y, Liao Q, Zhang W, Li X, Li Y, Li G, et al. Overexpression long non-coding RNA LINC00673 is associated with poor prognosis and promotes invasion and metastasis in tongue squamous cell carcinoma. Oncotarget. 2017;8:16621-32.Google Scholar
  7. 7.
    Bo H, Gong Z, Zhang W, Li X, Zeng Y, Liao Q, Chen P, Shi L, Lian Y, Jing Y, Tang K, Li Z, Zhou Y, Zhou M, Xiang B, Li X, et al. Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma. Oncotarget. 2015;6:20404–18.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014;110:164–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Kong R, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, Xia R, Wan L, Sun M, Wang ZX, De W, Zhang ZH. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer. 2015;14:82.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Fotouhi Ghiam A, Taeb S, Huang X, Huang V, Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, Bristow RG, Vesprini D, Boutros P, Liu SK. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget. 2017;8:4668–89.PubMedGoogle Scholar
  11. 11.
    Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X, Zhang W, Deng H, Zhou M, Peng S, Li G, Xiong W. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumour Biol. 2016;37:729–37.PubMedCrossRefGoogle Scholar
  12. 12.
    Killilea AN, Csencsits R, Le E, Patel AM, Kenny SJ, Xu K, Downing KH. Cytoskeletal organization in microtentacles. Exp Cell Res. 2017;357:291–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J Cell Sci. 2009;122:3037–49.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Wei F, Tang L, He Y, Wu Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Liao Q, Zhang W, Ni Q, Luo J, Li X, Li Y, Peng C, Chen X, Li G, Xiong W, Zeng Z. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell Death Dis. 2018;9(4):432.Google Scholar
  15. 15.
    Yang Y, Li M, Sun X, Zhou C, Wang Y, Wang L, Chen L, Liang Z, Zhu L, Yang H. The selective cytotoxicity of DSF-cu attributes to the biomechanical properties and cytoskeleton rearrangements in the normal and cancerous nasopharyngeal epithelial cells. Int J Biochem Cell Biol. 2017;84:96–108.PubMedCrossRefGoogle Scholar
  16. 16.
    Dugina V, Alieva I, Khromova N, Kireev I, Gunning PW, Kopnin P. Interaction of microtubules with the actin cytoskeleton via cross-talk of EB1-containing +TIPs and gamma-actin in epithelial cells. Oncotarget. 2016;7:72699–715.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Paavilainen VO, Bertling E, Falck S, Lappalainen P. Regulation of cytoskeletal dynamics by actin-monomer-binding proteins. Trends Cell Biol. 2004;14:386–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Terry SJ, Dona F, Osenberg P, Carlton JG, Eggert US. Capping protein regulates actin dynamics during cytokinetic midbody maturation. Proc Natl Acad Sci U S A. 2018;115:2138–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Liu JJ, Liu JY, Chen J, Wu YX, Yan P, Ji CD, Wang YX, Xiang DF, Zhang X, Zhang P, Cui YH, Wang JM, Bian XW, Qian F. Scinderin promotes the invasion and metastasis of gastric cancer cells and predicts the outcome of patients. Cancer Lett. 2016;376:110–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Molinie N, Gautreau A. The Arp2/3 regulatory system and its deregulation in Cancer. Physiol Rev. 2018;98:215–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Dimchev G, Steffen A, Kage F, Dimchev V, Pernier J, Carlier MF, Rottner K. Efficiency of lamellipodia protrusion is determined by the extent of cytosolic actin assembly. Mol Biol Cell. 2017;28:1311–25.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Bugyi B, Carlier MF. Control of actin filament treadmilling in cell motility. Annu Rev Biophys. 2010;39:449–70.PubMedCrossRefGoogle Scholar
  23. 23.
    Andrianantoandro E, Pollard TD. Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin. Mol Cell. 2006;24:13–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Maciver SK, Hussey PJ. The ADF/cofilin family: actin-remodeling proteins. Genome Biol. 2002;3:reviews3007.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Heinz LS, Muhs S, Schiewek J, Grub S, Nalaskowski M, Lin YN, Wikman H, Oliveira-Ferrer L, Lange T, Wellbrock J, Konietzny A, Mikhaylova M, Windhorst S. Strong fascin expression promotes metastasis independent of its F-actin bundling activity. Oncotarget. 2017;8:110077–91.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Wolff JR, Stuke K, Missler M, Tytko H, Schwarz P, Rohlmann A, Chao TI. Autocellular coupling by gap junctions in cultured astrocytes: a new view on cellular autoregulation during process formation. Glia. 1998;24:121–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Chandra Mangalhara K, Manvati S, Saini SK, Ponnusamy K, Agarwal G, Abraham SK, Bamezai RN. ERK2-ZEB1-miR-101-1 axis contributes to epithelial-mesenchymal transition and cell migration in cancer. Cancer Lett. 2017;391:59–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Lv X, He C, Huang C, Hua G, Wang Z, Remmenga SW, Rodabaugh KJ, Karpf AR, Dong J, Davis JS, Wang C. G-1 inhibits breast cancer cell growth via targeting colchicine-binding site of tubulin to interfere with microtubule assembly. Mol Cancer Ther. 2017;16(6):1080–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z, Xiong W.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):45.Google Scholar
  30. 30.
    Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak D, Mu H, Ruvolo V, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M. Focal adhesion kinase as a potential target in AML and MDS. Mol Cancer Ther. 2017;16(6):1133–44.PubMedCrossRefGoogle Scholar
  31. 31.
    He Y, Jing Y, Wei F, Tang Y, Yang L, Luo J, Yang P, Ni Q, Pang J, Liao Q, Xiong F, Guo C, Xiang B, Li X, Zhou M, Li Y, Xiong W, Zeng Z, Li G. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. Cell Death Dis. 2018;9(2):235.Google Scholar
  32. 32.
    Helfand BT, Chang L, Goldman RD. The dynamic and motile properties of intermediate filaments. Annu Rev Cell Dev Biol. 2003;19:445–67.PubMedCrossRefGoogle Scholar
  33. 33.
    Wei F, Wu Y, Tang L, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Liao Q, Zhang W, Zhou M, Xiang B, Li X, Li Y, Li G, Xiong W, Zeng Z. BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. Br J Cancer. 2018;118(2):233-47.Google Scholar
  34. 34.
    Lopez CG, Saldanha O, Huber K, Koster S. Lateral association and elongation of vimentin intermediate filament proteins: a time-resolved light-scattering study. Proc Natl Acad Sci U S A. 2016;113:11152–7.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Fogl C, Mohammed F, Al-Jassar C, Jeeves M, Knowles TJ, Rodriguez-Zamora P, White SA, Odintsova E, Overduin M, Chidgey M. Mechanism of intermediate filament recognition by plakin repeat domains revealed by envoplakin targeting of vimentin. Nat Commun. 2016;7:10827.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Costigliola N, Ding L, Burckhardt CJ, Han SJ, Gutierrez E, Mota A, Groisman A, Mitchison TJ, Danuser G. Vimentin fibers orient traction stress. Proc Natl Acad Sci U S A. 2017;114:5195–200.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Cheng F, Shen Y, Mohanasundaram P, Lindstrom M, Ivaska J, Ny T, Eriksson JE. Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-beta-slug signaling. Proc Natl Acad Sci U S A. 2016;113:E4320–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Maier J, Traenkle B, Rothbauer U. Visualizing epithelial-mesenchymal transition using the Chromobody technology. Cancer Res. 2016;76:5592–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Forest E, Logeay R, Geminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A. The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J Cell Biol. 2018;217(3):1047–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Chugh P, Clark AG, Smith MB, Cassani DAD, Dierkes K, Ragab A, Roux PP, Charras G, Salbreux G, Paluch EK. Actin cortex architecture regulates cell surface tension. Nat Cell Biol. 2017;19:689–97.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Petrie RJ, Doyle AD, Yamada KM. Random versus directionally persistent cell migration. Nat Rev Mol Cell Biol. 2009;10:538–49.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 2007;1773:642–52.PubMedCrossRefGoogle Scholar
  43. 43.
    Faix J, Grosse R. Staying in shape with formins. Dev Cell. 2006;10:693–706.PubMedCrossRefGoogle Scholar
  44. 44.
    Cojoc D, Difato F, Ferrari E, Shahapure RB, Laishram J, Righi M, Di Fabrizio EM, Torre V. Properties of the force exerted by filopodia and lamellipodia and the involvement of cytoskeletal components. PLoS One. 2007;2:e1072.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9:446–54.PubMedCrossRefGoogle Scholar
  46. 46.
    Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12:413–26.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Jerrell RJ, Parekh A. Cellular traction stresses mediate extracellular matrix degradation by invadopodia. Acta Biomater. 2014;10:1886–96.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Moore SW, Roca-Cusachs P, Sheetz MP. Stretchy proteins on stretchy substrates: the important elements of integrin-mediated rigidity sensing. Dev Cell. 2010;19:194–206.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Araki K, Ebata T, Guo AK, Tobiume K, Wolf SJ, Kawauchi K. p53 regulates cytoskeleton remodeling to suppress tumor progression. Cell Mol Life Sci. 2015;72:4077–94.PubMedCrossRefGoogle Scholar
  50. 50.
    Lv M, Zhong Z, Huang M, Tian Q, Jiang R, Chen J. lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. Biochim Biophys Acta. 2017;1864:1887–99.PubMedCrossRefGoogle Scholar
  51. 51.
    Zheng P, Xiong Q, Wu Y, Chen Y, Chen Z, Fleming J, Gao D, Bi L, Ge F. Quantitative proteomics analysis reveals novel insights into mechanisms of action of long noncoding RNA Hox transcript antisense intergenic RNA (HOTAIR) in HeLa cells. Mol Cell Proteomics. 2015;14:1447–63.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Chen R, Kong P, Zhang F, Shu YN, Nie X, Dong LH, Lin YL, Xie XL, Zhao LL, Zhang XJ, Han M. EZH2-mediated alpha-actin methylation needs lncRNA TUG1, and promotes the cortex cytoskeleton formation in VSMCs. Gene. 2017;616:52–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN, Zhou WP, Sun SH. Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology. 2013;57:1882–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, Wan L, Yan S, Ren SN, Wang ZX. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer. 2017;16:17.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Muller S, Raulefs S, Bruns P, Afonso-Grunz F, Plotner A, Thermann R, Jager C, Schlitter AM, Kong B, Regel I, Roth WK, Rotter B, Hoffmeier K, Kahl G, Koch I, Theis FJ, et al. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Mol Cancer. 2015;14:94.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Zhang YH, Fu J, Zhang ZJ, Ge CC, Yi Y. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res. 2016;8:5286–97.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Cai Q, Wang Z, Wang S, Weng M, Zhou D, Li C, Wang J, Chen E, Quan Z. Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1alpha via miR-138. Open Biol. 2017;7Google Scholar
  58. 58.
    Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer Oxaliplatin resistance and holds prognostic values in Colon Cancer. Mol Ther. 2016;24:2064–77.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Chen WM, Huang MD, Sun DP, Kong R, Xu TP, Xia R, Zhang EB, Shu YQ. Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer. Oncotarget. 2016;7:9773–87.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohee S, Olsen C, Guo M, Bontempi G, Sotiriou C, Defrance M, Fuks F. Portraying breast cancers with long noncoding RNAs. Sci Adv. 2016;2:e1600220.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Ji J, Tang J, Deng L, Xie Y, Jiang R, Li G, Sun B. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget. 2015;6:42813–24.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Wakatsuki T, Wysolmerski RB, Elson EL. Mechanics of cell spreading: role of myosin II. J Cell Sci. 2003;116:1617–25.PubMedCrossRefGoogle Scholar
  63. 63.
    Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–302.PubMedCrossRefGoogle Scholar
  64. 64.
    Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, et al. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 2009;459:1085–90.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–46.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Ono H, Motoi N, Nagano H, Miyauchi E, Ushijima M, Matsuura M, Okumura S, Nishio M, Hirose T, Inase N, Ishikawa Y. Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Med. 2014;3:632–42.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Wu XC, Wang SH, Ou HH, Zhu B, Zhu Y, Zhang Q, Yang Y, Li H. The NmrA-like family domain containing 1 pseudogene Loc344887 is amplified in gallbladder cancer and promotes epithelial-mesenchymal-transition. Chem Biol Drug Des. 2017;90(3):456–63.PubMedCrossRefGoogle Scholar
  68. 68.
    Xu Y, Wang B, Zhang F, Wang A, Du X, Hu P, Zhu Y, Fang Z. Long non-coding RNA CCAT2 is associated with poor prognosis in hepatocellular carcinoma and promotes tumor metastasis by regulating Snail2-mediated epithelial-mesenchymal transition. Onco Targets Ther. 2017;10:1191–8.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Gruenbaum Y, Aebi U. Intermediate filaments: a dynamic network that controls cell mechanics. F1000Prime Rep. 2014;6:54.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Wang Y, He H, Li W, Phay J, Shen R, Yu L, Hancioglu B, de la Chapelle A. MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. Proc Natl Acad Sci U S A. 2017;114:474–9.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, Goff BA, Hanash SM, Swisher EM. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer. 2012;22:546–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J, Xue Y. Gas5 exerts tumor-suppressive functions in human glioma cells by targeting miR-222. Mol Ther. 2015;23:1899–911.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Lappalainen P, Drubin DG. Cofilin promotes rapid actin filament turnover in vivo. Nature. 1997;388:78–82.PubMedCrossRefGoogle Scholar
  74. 74.
    Xue M, Pang H, Li X, Li H, Pan J, Chen W. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 2016;107:18–27.PubMedCrossRefGoogle Scholar
  75. 75.
    Parsons M, Adams JC. Rac regulates the interaction of fascin with protein kinase C in cell migration. J Cell Sci. 2008;121:2805–13.PubMedCrossRefGoogle Scholar
  76. 76.
    Vignjevic D, Kojima S, Aratyn Y, Danciu O, Svitkina T, Borisy GG. Role of fascin in filopodial protrusion. J Cell Biol. 2006;174:863–75.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;116:167–79.PubMedCrossRefGoogle Scholar
  78. 78.
    Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010;67:545–54.CrossRefGoogle Scholar
  79. 79.
    Symons M. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem Sci. 1996;21:178–81.PubMedCrossRefGoogle Scholar
  80. 80.
    Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–35.PubMedCrossRefGoogle Scholar
  81. 81.
    Pruitt K, Ras DCJ. Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001;171:1–10.PubMedCrossRefGoogle Scholar
  82. 82.
    Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–69.PubMedCrossRefGoogle Scholar
  83. 83.
    Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, Leung S, Wiseman SM, Nabi IR. Phosphorylated caveolin-1 regulates rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 2008;68:8210–20.PubMedCrossRefGoogle Scholar
  84. 84.
    Garcia-Mariscal A, Li H, Pedersen E, Peyrollier K, Ryan KM, Stanley A, Quondamatteo F, Brakebusch C. Loss of RhoA promotes skin tumor formation and invasion by upregulation of RhoB. Oncogene. 2018;37:847–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Alkasalias T, Alexeyenko A, Hennig K, Danielsson F, Lebbink RJ, Fielden M, Turunen SP, Lehti K, Kashuba V, Madapura HS, Bozoky B, Lundberg E, Balland M, Guven H, Klein G, Gad AK, et al. RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo. Proc Natl Acad Sci U S A. 2017;114:E1413–21.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Egami Y, Kawai K, Araki N. RhoC regulates the actin remodeling required for phagosome formation during FcgammaR-mediated phagocytosis. J Cell Sci. 2017;130:4168–79.PubMedCrossRefGoogle Scholar
  87. 87.
    Chuang YY, Tran NL, Rusk N, Nakada M, Berens ME, Symons M. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res. 2004;64:8271–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Arana E, Vehlow A, Harwood NE, Vigorito E, Henderson R, Turner M, Tybulewicz VL, Batista FD. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formation. Immunity. 2008;28:88–99.PubMedCrossRefGoogle Scholar
  89. 89.
    Donnelly SK, Cabrera R, Mao SPH, Christin JR, Wu B, Guo W, Bravo-Cordero JJ, Condeelis JS, Segall JE, Hodgson L. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017;216:4331–49.PubMedCrossRefGoogle Scholar
  90. 90.
    Richerioux N, Blondeau C, Wiedemann A, Remy S, Vautherot JF, Denesvre C. Rho-ROCK and Rac-PAK signaling pathways have opposing effects on the cell-to-cell spread of Marek's disease virus. PLoS One. 2012;7:e44072.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Riento K, Villalonga P, Garg R, Ridley A. Function and regulation of RhoE. Biochem Soc Trans. 2005;33:649–51.PubMedCrossRefGoogle Scholar
  92. 92.
    Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol. 2008;10:127–37.PubMedCrossRefGoogle Scholar
  93. 93.
    Riento K, Ridley A. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446–56.PubMedCrossRefGoogle Scholar
  94. 94.
    Rath N, Morton JP, Julian L, Helbig L, Kadir S, McGhee EJ, Anderson KI, Kalna G, Mullin M, Pinho AV, Rooman I, Samuel MS, Olson MF. ROCK signaling promotes collagen remodeling to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO Mol Med. 2017;9:198–218.PubMedCrossRefGoogle Scholar
  95. 95.
    Newell-Litwa KA, Badoual M, Asmussen H, Patel H, Whitmore L, Horwitz AR. ROCK1 and 2 differentially regulate actomyosin organization to drive cell and synaptic polarity. J Cell Biol. 2015;210:225–42.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Jerrell RJ, Parekh A. Matrix rigidity differentially regulates invadopodia activity through ROCK1 and ROCK2. Biomaterials. 2016;84:119–29.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Jerrell RJ, Leih MJ, Parekh A. The ROCK isoforms differentially regulate the morphological characteristics of carcinoma cells. Small GTPases. 2017:1–7.Google Scholar
  98. 98.
    Darenfed H, Dayanandan B, Zhang T, Hsieh SH, Fournier AE, Mandato CA. Molecular characterization of the effects of Y-27632. Cell Motil Cytoskeleton. 2007;64:97–109.PubMedCrossRefGoogle Scholar
  99. 99.
    Jansen S, Gosens R, Wieland T, Schmidt M. Paving the rho in cancer metastasis: rho GTPases and beyond. Pharmacol Ther. 2018;183:1–21.PubMedCrossRefGoogle Scholar
  100. 100.
    Sun CX, Magalhaes MA, Glogauer M. Rac1 and Rac2 differentially regulate actin free barbed end formation downstream of the fMLP receptor. J Cell Biol. 2007;179:239–45.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Pellegrin S, Mellor H. The rho family GTPase Rif induces filopodia through mDia2. Curr Biol. 2005;15:129–33.PubMedCrossRefGoogle Scholar
  102. 102.
    Ridley AJ. Life at the leading edge. Cell. 2011;145:1012–22.PubMedCrossRefGoogle Scholar
  103. 103.
    Lizarraga F, Poincloux R, Romao M, Montagnac G, Le Dez G, Bonne I, Rigaill G, Raposo G, Chavrier P. Diaphanous-related formins are required for invadopodia formation and invasion of breast tumor cells. Cancer Res. 2009;69:2792–800.PubMedCrossRefGoogle Scholar
  104. 104.
    Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosano L. Endothelin a receptor drives invadopodia function and cell motility through the beta-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene. 2016;35:3432–42.PubMedCrossRefGoogle Scholar
  105. 105.
    Poincloux R, Lizarraga F, Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci. 2009;122:3015–24.PubMedCrossRefGoogle Scholar
  106. 106.
    Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J, D'Souza-Schorey C, Chavrier P. The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol. 2008;181:985–98.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S, Liu X. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma. J Orthop Res. 2016;34:932–41.PubMedCrossRefGoogle Scholar
  108. 108.
    Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, Zhang Y, Xing Y, Xi T. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016;472:262–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Tang Y, He Y, Shi L, Yang L, Wang J, Lian Y, Fan C, Zhang P, Guo C, Zhang S, Gong Z, Li X, Xiong F, Li X, Li Y, Li G, Xiong W, Zeng Z.  Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017; 8(24):39001-11.Google Scholar
  110. 110.
    Wang C, Yan G, Zhang Y, Jia X, Bu P. Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1. Neoplasma. 2015;62:541–9.PubMedCrossRefGoogle Scholar
  111. 111.
    Shi S, Peng Q, Shao X, Xie J, Lin S, Zhang T, Li Q, Li X, Lin Y. Self-assembled tetrahedral DNA nanostructures promote adipose-derived stem cell migration via lncRNA XLOC 010623 and RHOA/ROCK2 signal pathway. ACS Appl Mater Interfaces. 2016;8:19353–63.PubMedCrossRefGoogle Scholar
  112. 112.
    Ge Z, Cheng Z, Yang X, Huo X, Wang N, Wang H, Wang C, Gu D, Zhao F, Yao M, Fan J, Qin W. Long noncoding RNA SchLAH suppresses metastasis of hepatocellular carcinoma through interacting with fused in sarcoma. Cancer Sci. 2017;108:653–62.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Tang Y, Wang J, Lian Y, Fan C, Zhang P, Wu Y, Li X, Xiong F, Li X, Li G, Xiong W, Zeng Z.  Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer. Mol Cancer. 2017;16(1):42.Google Scholar
  114. 114.
    Wu D, Chen X, Sun K, Wang L, Chen S, Zhao Y. Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017;16:138.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Yanyan Tang
    • 1
    • 2
  • Yi He
    • 1
    • 2
  • Ping Zhang
    • 2
    • 6
  • Jinpeng Wang
    • 2
  • Chunmei Fan
    • 2
  • Liting Yang
    • 2
  • Fang Xiong
    • 5
  • Shanshan Zhang
    • 2
    • 3
  • Zhaojian Gong
    • 2
  • Shaolin Nie
    • 1
  • Qianjin Liao
    • 1
    • 2
  • Xiayu Li
    • 2
    • 4
  • Xiaoling Li
    • 2
    • 3
  • Yong Li
    • 5
  • Guiyuan Li
    • 1
    • 2
    • 3
  • Zhaoyang Zeng
    • 1
    • 2
    • 3
  • Wei Xiong
    • 1
    • 2
    • 3
  • Can Guo
    • 1
    • 2
    • 3
  1. 1.Department of Colorectal SurgeryHunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityChangshaChina
  2. 2.The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research InstituteCentral South UniversityChangshaChina
  3. 3.The Key Laboratory of Carcinogenesis of the Chinese Ministry of HealthXiangya Hospital, Central South UniversityChangshaChina
  4. 4.Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Disease Genome Research CenterThe Third Xiangya Hospital, Central South UniversityChangshaChina
  5. 5.Department of Cancer Biology, Lerner Research InstituteCleveland ClinicClevelandUSA
  6. 6.School of Electronics and Information EngineeringHunan University of Science and EngineeringYongzhouChina

Personalised recommendations